Aurinia Pharmaceuticals (AUPH) Reports Prelim Q4 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St futures recover as oil slides ahead of inflation test
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- S&P 500, Dow futures attempt recovery ahead of inflation report
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
January 5, 2024 6:00 AM ESTPreliminary unaudited total net revenue for the fourth quarter and full year 2023 of approximately $45 million and $176 million
Preliminary unaudited net product revenue for the fourth quarter and full year 2023 of approximately $42 million and $159 million
Approximately $351 million of cash, cash equivalents, restricted cash and investments as of December 31, 2023 (unaudited)
Net product revenue guidance for 2024 in the range of $200 -$220 million; targeting to be cash flow positive in the second half of 2024
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:... More
